KKStock A drug shortage impacting supplies of Eli Lilly's ( NYSE: LLY ) GLP-1 drugs for, respectively, diabetes and weight loss, Mounjaro and Zepbound, appears to be alleviating. According to a June 4 revision of the U.S.
FDA's drug shortage webpage, half of the dosage strengths for both Mounjaro and Zepbound have normal availability. Both drugs have six dosage strengths each. The other dosages are still in limited availability through the end of Q2.
However, the current situation is an improvement from April when only one dosage strength for each drug had normal availability. More on Eli Lilly Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases SA Asks: Which weight-loss stocks should investors be watching?.
